Imidazolopiperazines: Hit to Lead Optimization of New Antimalarial Agents
Citations Over TimeTop 10% of 2011 papers
Abstract
Starting from a hit series from a GNF compound library collection and based on a cell-based proliferation assay of Plasmodium falciparum, a novel imidazolopiperazine scaffold was optimized. SAR for this series of compounds is discussed, focusing on optimization of cellular potency against wild-type and drug resistant parasites and improvement of physiochemical and pharmacokinetic properties. The lead compounds in this series showed good potencies in vitro and decent oral exposure levels in vivo. In a Plasmodium berghei mouse infection model, one lead compound lowered the parasitemia level by 99.4% after administration of 100 mg/kg single oral dose and prolonged mice survival by an average of 17.0 days. The lead compounds were also well-tolerated in the preliminary in vitro toxicity studies and represents an interesting lead for drug development.
Related Papers
- → Plasmodium berghei: Recombinant Interferon-γ and the Development of Parasitemia and Cerebral Lesions in Malaria-Infected Mice(1993)35 cited
- Humoral immunity in rodent malaria. I. Estimation of parasitemia by electronic particle counting.(1969)
- → Effect of Temperature and Clofibrate on Plasmodium Berghei Infection in Mice(1979)8 cited
- → Correlation of Parasitaemia and Anemia in Mice Infected with Plasmodium berghei ANKA(2023)1 cited
- → Pathologic physiology and chemotherapy of Plasmodium berghei I. Suppression of parasitemia by sulfones and sulfonamides in mice(1967)26 cited